Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study.

MLA

Hongxin Li, et al. “Efficacy and Patient-Reported Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Aumolertinib as First-Line Therapy: A Real-World Study.” Frontiers in Pharmacology, Sept. 2024, pp. 1–9. EBSCOhost, https://doi.org/10.3389/fphar.2024.1444707.

APA

Hongxin Li, Wen Zhao, Caiyun Chang, Tiantian Xuan, Chengjun Wang, Rongyu Zhang, Chuang Yang, Jian Wang, Cuihua Yi, Xiuwen Wang, Shuwen Yu, & Jisheng Li. (2024). Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study. Frontiers in Pharmacology, 1–9. https://doi.org/10.3389/fphar.2024.1444707

Chicago

Hongxin Li, Wen Zhao, Caiyun Chang, Tiantian Xuan, Chengjun Wang, Rongyu Zhang, Chuang Yang, et al. 2024. “Efficacy and Patient-Reported Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Aumolertinib as First-Line Therapy: A Real-World Study.” Frontiers in Pharmacology, September, 1–9. doi:10.3389/fphar.2024.1444707.